Drug-Drug Interaction Study Between DWC20155 / DWC20156 and DWC20161 in Healthy Volunteers

Daewoong Pharmaceutical

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: DWC20161; Drug: Co-administration of DWC20155/DWC20156

Study type: Interventional

Funder types: Industry

Identifiers

NCT02947139

DW_DWJ1366003

Details and patient eligibility

About

A randomized, open label, crossover study to explore drug-drug interactions between DWC20155 / DWC20156 and DWC20161 in Healthy Volunteers

Enrollment: 53 patients

Sex: All

Ages: 19 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Accepts healthy volunteers

Exclusion criteria

• Who has allergy to investigational product

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

53 participants in 2 patient groups

Study effect of DWC20161 on DWC20155/DWC20156 PK

Experimental group

Description:

To study effect of DWC20161 on DWC20155/DWC20156 PK

Treatment:

Drug: DWC20161

Drug: Co-administration of DWC20155/DWC20156

Study effect of DWC20155/DWC20156 on DWC20161 PK

Experimental group

Description:

To study effect of DWC20155/DWC20156 on DWC20161 PK

Treatment:

Drug: DWC20161

Drug: Co-administration of DWC20155/DWC20156